News
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA reduziert Ausblick für Geschäftsjahr 2022 aufgrund Verschärfung nachteiliger Faktoren im U.S. Arbeitsmarkt und globaler Inflation und zieht Ziele für 2025 zurück
Lonza erzielt im ersten Halbjahr 2022 ein solides Ergebnis mit einem Umsatzwachstum von 16.8% (kWk) und einer Kern-EBITDA-Marge von 33.1%
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Maria Soler Nunez appointed as Head, Group Operations
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
DGAP-News: Carl Zeiss Meditec erzielt im ersten Halbjahr 2021/22 weiteres starkes Wachstum bei Umsatz und Auftragseingang
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care berichtet Ergebnisse für das erste Quartal im Rahmen seiner Erwartungen trotz erheblicher Belastungen
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet folgt Rice Powell als Vorstandsvorsitzende von Fresenius Medical Care
DGAP-News: Carl Zeiss Meditec erwirbt zwei Hersteller für chirurgische Instrumente
Johnson & Johnson Update: ist die Abspaltung gesund oder drohen Probleme?
Abbvie Inc - Technical Analysis
.png?locale=us "FinanceClub_UoM")
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:
-
Jereme Sylvain, Executive Vice President and Chief
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI
Agilent to Present at Evercore ISI Virtual Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the company’s presentation at the Evercore ISI Virtual Healthcare Conference will be made available by webcast. The details:
Evercore ISI
Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the fourth quarter ended Oct. 31, 2021, up 12% year over year (core(1) growth of 11%). Revenue for the full year was
Humana Expands Value-Based Agreement with Hutchinson Clinic to Increase Medicare Advantage Access in Central Kansas
Humana Inc. (NYSE: HUM), a leading health and wellness company, has expanded its value-based care agreement with Hutchinson Clinic, a physician specialty group with a 60-year legacy of focusing on
Humana Announces Value-Based Agreement with Allina Health in Minnesota
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Allina Health are expanding their existing agreement to focus on value-based care for Humana’s Medicare Advantage members in
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the
Dr. Otis Brawley Named to Agilent Board of Directors
Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Otis W. Brawley, a Bloomberg Distinguished Professor with the Department of Oncology and Epidemiology at the Johns Hopkins University
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™
Agilent Increases Cash Dividend to 21 Cents Per Share
Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 21 cents per share of common stock, reflecting an 8% increase over the previous quarter. The